The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an increase over baseline at 12 months.
The trial involved 453 subjects with high-grade serous epithelial platinum-resistant ovarian cancer.
Scholar Rock’s stock is due to drop by 7.49% following the news, according to pre-market estimates.
The trial’s primary objective is to assess PALI-2108’s tolerability, pharmacokinetics and safety in healthy volunteers.
Results saw all 24 healthy volunteers who made it to the 72-week mark still had effective levels of dMAB in their systems.
The companies will retain commercial rights to their compounds.
